Stock listing
ASX:ADR Adherium Ltd. Share Price
Home listing (ASX) of Adherium Ltd.
Follow Adherium Ltd. into a list and get an email when it puts out news.
Share price · ASX:ADR
$0.048 AUD 0.000 (0.0%)
Close on Nov 19, 2026
- Day range
- $0.048 – $0.048 AUDNov 19, 2026
- Volume
- 48 sharesNov 19, 2026
- Market cap
- $2.63M AUDAt the close on Nov 19, 2026 · price × 54.89M shares outstanding
- 52-week range
- $0.048 – $0.800 AUDLowest and highest trades, Nov 20, 2025 – Nov 19, 2026
- Traded on an average day
- $2,965 AUDMedian day 7,515 shares · last 3 months, Aug 21, 2026 – Nov 19, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| ASX:ADR · Home | $0.048 AUD | 0.000 (0.0%) | 48 | $0.048 | $0.048 | $0.048 | $0.048 | Close on Nov 19, 2026 |
Daily closes
Last 3 months, Aug 21, 2026 – Nov 19, 2026 · ASX:ADR · AUD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.048 | 0.000 | 0.0% | $0.048 | $0.048 | $0.048 | 48 | |
| $0.048 | 0.000 | 0.0% | $0.048 | $0.048 | $0.048 | 48 | |
| $0.048 | -0.002 | -4.0% | $0.050 | $0.050 | $0.048 | 109,028 | |
| $0.050 | -0.002 | -3.8% | $0.052 | $0.052 | $0.050 | 69,391 | |
| $0.052 | 0.000 | 0.0% | $0.053 | $0.053 | $0.052 | 80,252 | |
| $0.052 | -0.009 | -14.8% | $0.055 | $0.055 | $0.052 | 276,115 | |
| $0.061 | -0.006 | -9.0% | $0.061 | $0.061 | $0.061 | 18 | |
| $0.067 | 0.000 | 0.0% | $0.068 | $0.068 | $0.067 | 7,515 | |
| $0.067 | +0.004 | +6.3% | $0.063 | $0.067 | $0.063 | 72,078 | |
| $0.063 | -0.007 | -10.0% | $0.069 | $0.069 | $0.060 | 238,410 | |
| $0.070 | 0.000 | 0.0% | $0.070 | $0.070 | $0.070 | 127,404 | |
| $0.070 | 0.000 | 0.0% | $0.070 | $0.070 | $0.070 | 319 | |
| $0.070 | 0.000 | 0.0% | $0.070 | $0.070 | $0.070 | 37,500 | |
| $0.070 | 0.000 | 0.0% | $0.072 | $0.072 | $0.070 | 32,453 | |
| $0.070 | -0.007 | -9.1% | $0.078 | $0.078 | $0.070 | 169,585 | |
| $0.077 | +0.002 | +2.7% | $0.076 | $0.077 | $0.076 | 7,207 | |
| $0.075 | -0.001 | -1.3% | $0.076 | $0.077 | $0.075 | 6,758 | |
| $0.076 | -0.006 | -7.3% | $0.076 | $0.076 | $0.075 | 77,992 | |
| $0.082 | 0.000 | 0.0% | $0.082 | $0.082 | $0.082 | 316 | |
| $0.082 | 0.000 | 0.0% | $0.082 | $0.082 | $0.082 | 316 | |
| $0.082 | 0.000 | 0.0% | $0.082 | $0.082 | $0.082 | 300 | |
| $0.082 | 0.000 | 0.0% | $0.082 | $0.082 | $0.082 | 5,292 | |
| $0.082 | 0.000 | 0.0% | $0.082 | $0.082 | $0.082 | 19,173 | |
| $0.082 | +0.002 | +2.5% | $0.082 | $0.082 | $0.082 | 32,327 | |
| $0.080 | -0.002 | -2.4% | $0.080 | $0.082 | $0.080 | 93,856 | |
| $0.082 | -0.003 | -3.5% | $0.084 | $0.084 | $0.082 | 71,459 | |
| $0.085 | 0.000 | 0.0% | $0.085 | $0.085 | $0.085 | 5,882 | |
| $0.085 | 0.000 | 0.0% | $0.085 | $0.085 | $0.085 | 4 | |
| $0.085 | -0.015 | -15.0% | $0.085 | $0.085 | $0.085 | 141,469 | |
| $0.100 | +0.001 | +1.0% | $0.098 | $0.100 | $0.098 | 22,390 | |
| $0.099 | -0.001 | -1.0% | $0.099 | $0.099 | $0.099 | 199 | |
| $0.100 | 0.000 | 0.0% | $0.100 | $0.100 | $0.100 | 500 | |
| $0.100 | 0.000 | 0.0% | $0.100 | $0.100 | $0.100 | 500 | |
| $0.100 | 0.000 | 0.0% | $0.099 | $0.100 | $0.095 | 11,724 | |
| $0.100 | 0.000 | 0.0% | $0.100 | $0.100 | $0.100 | 22 | |
| $0.100 | 0.000 | 0.0% | $0.100 | $0.100 | $0.100 | 50 | |
| $0.100 | 0.000 | 0.0% | $0.100 | $0.100 | $0.100 | 50 | |
| $0.100 | 0.000 | 0.0% | $0.100 | $0.100 | $0.100 | 1,563 | |
| $0.100 | 0.000 | 0.0% | $0.100 | $0.100 | $0.100 | 10,017 |
Splits
3 splits since 2023 · ASX:ADR · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-100 | Consolidation | |
| 7-for-6 | Split | |
| 1-for-15 | Consolidation |
- Ticker
- ASX:ADR
- Asset type
- Stock
- Sector
- Health care
- Industry
- Health care services
- Exchange
- ASX
- Currency
- AUD
What changed lately
Latest news release · Nov 19, 2026
Change in substantial holding
Latest deck · July 2026
Investor Presentation (July 2026)
Investor deck · 24 slides
Latest news
Quarterly Activities/Appendix 4C Cash Flow Report
Oct 30, 2026
Closed $0.067 (0.0%) on Nov 4, 2026
Additional $750,000 Loan Facility from Barvest Ventures
Oct 30, 2026
Closed $0.067 (0.0%) on Nov 4, 2026
Partnership with Florida Lung, Asthma & Sleep Specialists
Oct 25, 2026
Closed $0.067 (+6.3%) on Oct 26, 2026
Appointment of Chief Financial Officer
Oct 11, 2026
Closed $0.07 (-9.1%) on Oct 12, 2026
AUD$700,000 Short-Term Loan Facility from Barvest Ventures
Oct 6, 2026
Closed $0.077 (+2.7%) on Oct 9, 2026
Appendix 4G & Corporate Governance Statement
Sep 30, 2026
Closed $0.076 (-7.3%) on Oct 1, 2026
Annual Report to shareholders
Sep 30, 2026
Closed $0.076 (-7.3%) on Oct 1, 2026
Adherium Consolidates Funding into A$4.67M Term Loan
Sep 15, 2026
Closed $0.082 (-3.5%) on Sep 17, 2026
Adherium Ltd. on 6ix
- Sector
- Health care
- Industry
- Health care services
- News releases
- 30 in the last 12 months · 127 in all · newest Nov 19, 2026 · oldest 2016
- Decks
- 32 decks · latest July 2026
Where Adherium Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| ASX:ADR · Home listing · This page | ASX | Australia | AUD |
| OTC:ADRMF | OTC | United States | USD |
Valuation
EV/sales 7.0× against a median of 0.9×: 8th lowest of 9 Health care services companies shown. Statements: Year to Jun 30, 2025 · price Nov 19, 2026
- Enterprise value
- $5.71M AUD
- P/E
- Loss
- EV/sales
- 7.0×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- 13.6%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- Negative equity
- Beta
- No index for this market yet
Health care services: the 10 companies nearest in size, of 419 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Adherium Ltd. · ASX:ADR | US$1.74M | US$3.78M | n/a | 7.0× | n/a | n/a | n/a | n/a | n/a |
| Feedback plc · LSE:FDBK | US$2.24M | −US$2.77M | n/a | −2.4× | n/a | 0.4× | −826.2% | 0.0× | n/a |
| Predilife SA · EURONEXT:ALPRE | US$2.16M | US$7.61M | n/a | 6.2× | n/a | n/a | −315.3% | n/a | n/a |
| RMH Holdings Limited · HKEX:8437 | US$2.12M | US$2.58M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| INVO Fertility, Inc. · NASDAQ:IVF | US$2.10M | US$3.06M | n/a | 0.4× | n/a | 0.1× | −71.4% | 0.1× | 1.62 |
| HealthLynked Corp. · OTC:HLYK | US$2.07M | US$2.05M | n/a | 1.8× | n/a | n/a | −351.6% | n/a | -0.67 |
| Grey Matters Health Inc · CSE:GREY | US$1.98M | US$1.95M | n/a | n/a | n/a | 1.6× | n/a | 0.0× | 0.43 |
| Global Health Limited · ASX:GLH | US$1.95M | US$2.54M | n/a | 0.5× | n/a | n/a | −10.5% | n/a | n/a |
| Telemedycyna Polska S.A. · NEWCONNECT:TMP | US$1.76M | US$1.73M | n/a | 1.3× | n/a | n/a | −14.9% | n/a | n/a |
| Accendra Health, Inc. · NYSE:ACH | US$1.57M | US$9.96M | n/a | 0.0× | 0.1× | n/a | −6.7% | n/a | 0.51 |
| CardioComm Solutions, Inc. · TSXV:EKG | US$1.38M | US$1.62M | n/a | 8.5× | n/a | n/a | −194.6% | n/a | 0.00 |
| Median of the others | US$2.02M | US$2.30M | 0.9× | 0.1× | 0.4× | −132.9% | 0.0× | 0.43 |
Forecasts
Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.
- Price target
- 0.89 AUD · Analysts' mean
- EPS, year to Jun 2027
- -0.098 · 1 analyst
- Revenue, year to Jun 2027
- 9.61M · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Dawn Bitz | CEO |
| John Perry | Interim Chief Executive Officer & Chief Commercial Officer |
| Brad Wilson | Chief Financial Officer |
| Daniel Kaplon | Chief Financial Officer |
| Catherine Morgan | Head of Regulatory & Quality |
| David Haddad | Head of Product |
| Hetal Dhruve | Head of Medical & Clinical Affairs |
Board
| Director | Role |
|---|---|
| George Baran | Non-Executive Chair |
| James Ward-Lilley | Chairman of the Board |
| Dawn Bitz | CEO |
| Jeremy Curnock Cook | Independent Non-Executive Director |
| Keven Gessner | Non-Executive Director |
| Lou Panaccio | Independent Non-Executive Director |
| Victoria Durrans | Independent Non-Executive Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q4 2025 | Sep 30, 2025 | 0.0% |
| Q2 2025 | Feb 28, 2025 | −15.4% |
| Q2 2023 | Feb 27, 2023 · After close | −14.3% |
| Q4 2022 | Aug 31, 2022 · Before open | |
| Q2 2022 | Feb 25, 2022 | +9.1% |
| Q4 2021 | Aug 27, 2021 | −6.3% |
| Q2 2021 | Feb 25, 2021 | 0.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (July 2026) | Investor deck | 24 slides | July 2026 |
| Investor Webinar June 2026 | Conference | 19 slides | June 2026 |
| Investor Presentation (February 2026) | Investor deck | 42 slides | Feb 16, 2026 |
| Investor Presentation (February 2026) | Investor deck | 36 slides | February 2026 |
| Investor Webinar (December 2025) | Conference | 15 slides | Dec 1, 2025 |
| Shareholder Meeting (November 2025) | Shareholder meeting | 30 slides | Nov 18, 2025 |
| Investor Presentation (October 2025) | Investor deck | 26 slides | October 2025 |
| Investor Presentation (February 2025) | Investor deck | 31 slides | February 2025 |
| Investor Presentation (April 2024) | Investor deck | 28 slides | Apr 26, 2024 |
| Shareholder Meeting (November 2023) | Shareholder meeting | 18 slides | Nov 30, 2023 |
All 32 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2023) | Investor deck | 17 slides | Nov 22, 2023 |
| 41st Annual J.P. Morgan Healthcare Conference 2023 | Conference | 19 slides | Jan 10, 2023 |
| Investor Presentation (October 2022) | Investor deck | 11 slides | Oct 21, 2022 |
| Investor Presentation (August 2022) | Investor deck | 18 slides | August 2022 |
| Investor Presentation (April 2021) | Investor deck | 10 slides | April 2021 |
| Investor Presentation (March 2021) | Investor deck | 23 slides | Mar 18, 2021 |
| Shareholder Meeting (November 2020) | Shareholder meeting | 13 slides | November 2020 |
| Shareholder Meeting (July 2020) | Shareholder meeting | 18 slides | Jul 24, 2020 |
| Investor Presentation (December 2019) | Investor deck | 25 slides | Dec 19, 2019 |
| Shareholder Meeting (November 2019) | Shareholder meeting | 15 slides | November 2019 |
| Shareholder Meeting (November 2018) | Shareholder meeting | 16 slides | Nov 20, 2018 |
| Investor Conference Call Q1 Fiscal Year 2019 | Conference | 13 slides | Oct 31, 2018 |
| FY2018 Earnings Presentation | Earnings | 14 slides | Aug 28, 2018 |
| Q3 FY18 Earnings Presentation | Earnings | 12 slides | May 4, 2018 |
| H1 2018 Earnings Presentation | Earnings | 13 slides | Feb 8, 2018 |
| Shareholder Meeting (November 2017) | Shareholder meeting | 14 slides | Nov 29, 2017 |
| Conference Presentation (August 2017) | Conference | 19 slides | Aug 29, 2017 |
| JP Morgan Conference 2017 | Conference | 15 slides | Jan 11, 2017 |
| AusBiotech 2016 | Conference | 4 slides | Oct 26, 2016 |
| Non-Deal Roadshow (October 2016) | Roadshow | 20 slides | Oct 26, 2016 |
| H1 FY2016 Earnings Presentation | Earnings | 33 slides | Mar 7, 2016 |
| EBD Biotech Showcase 2016 | Conference | 40 slides | Jan 11, 2016 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of new shares Closed: A$1.34M raised · A$0.003 a share · Stralis Capital Partners Pty Limited +2 Dealers: Stralis Capital Partners Pty Limited (lead), PAC Partners Securities Pty Ltd, Volatility Pty Ltd (InvestHouse) Use of proceeds: Commercial initiatives focused on growth in the Remote Patient Monitoring channel and progress toward value-based care contracts with U.S. insurers | Feb 18, 2026 | US$945,779 |
| Rights offering of new shares Tranche closed: A$5.37M raised · A$0.003 a share · Stralis Capital Partners Pty Limited +2 Dealers: Stralis Capital Partners Pty Limited (lead), PAC Partners Securities Pty Ltd, Volatility Pty Ltd (InvestHouse) Buyers: Trudell Medical Ltd (firm commitment of A$2.0 million, greater than its pro-rata entitlement under the Institutional Entitlement Offer) Use of proceeds: Commercial initiatives focused on growth in the Remote Patient Monitoring channel and progress toward value-based care contracts with U.S. insurers | Feb 18, 2026 | US$3.79M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in AUD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 817.2K | 841.0K | 3.19M | 529.0K | 401.0K | 2.22M | 2.78M | 5.87M | 2.35M | 2.10M |
| Cost of revenue | 705.9K | 573.3K | 1.50M | 1.22M | 1.19M | 1.54M | 1.13M | 1.10M | 1.19M | 1.07M |
| Gross profit | 111.4K | 267.7K | 1.69M | -690.0K | -789.0K | 677.0K | 1.65M | 4.77M | 1.16M | 1.03M |
| Research and development | 3.44M | 4.14M | 4.72M | 5.88M | 5.48M | 3.95M | 5.12M | 4.45M | 4.24M | 2.17M |
| Selling, general and administrative | 5.49M | 5.06M | 4.85M | 5.36M | 6.14M | 3.77M | 4.34M | 5.41M | 6.26M | 3.12M |
| Operating income | -12.5M | -12.1M | -11.9M | -12.8M | -12.4M | -8.92M | -11.6M | -9.64M | -13.8M | -6.68M |
| Depreciation and amortization | 103.3K | 108.1K | 191.0K | 186.0K | 145.0K | 335.0K | 413.0K | 310.0K | 270.0K | 121.6K |
| EBITDA | -12.4M | -12.0M | -11.7M | -12.7M | -12.2M | -8.59M | -11.2M | -9.33M | -13.6M | -6.56M |
| Interest expense | 228.7K | 2.07K | 6.00K | 1.00K | 2.24M | 2.60M | 4.00K | 0 | 0 | 303.2K |
| Income before tax | -12.7M | -10.2M | -11.7M | -12.9M | -15.4M | -11.4M | -11.8M | -9.34M | -12.8M | -6.31M |
| Income tax | -1.19M | -1.45M | -1.84M | -2.81M | -370.0K | 128.7K | 91.1K | -98.0K | -883.0K | 0 |
| Net income | -12.7M | -10.2M | -9.86M | -10.0M | -15.0M | -11.4M | -11.8M | -9.34M | -12.8M | -6.31M |
| Earnings per share, basic | -1.41 | -2.75 | -3.62 | -6.93 | -25.03 | -54.10 | -1.02 | -80.76 | -0.08 | -75.51 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 43.3K | 6.20M | 9.08M | 5.28M | 15.2M | 4.58M | 763.0K | 12.1M | 22.8M | 27.2M |
| Short-term investments | 0 | 427.0K | ||||||||
| Receivables | 80.7K | 1.80M | 1.97M | 420.0K | 567.0K | 624.0K | 287.0K | 1.21M | 826.0K | 948.0K |
| Inventory | 1.84M | 1.58M | 1.24M | 1.07M | 962.0K | 1.12M | 417.0K | 509.0K | 726.0K | 418.0K |
| Current assets | 3.40M | 9.73M | 12.5M | 8.22M | 16.9M | 6.48M | 1.77M | 14.5M | 24.4M | 28.6M |
| Property, plant and equipment | 127.0K | 313.0K | 127.0K | 235.0K | 380.0K | 515.0K | 417.0K | 298.0K | ||
| Total assets | 3.52M | 9.89M | 12.7M | 8.53M | 17.0M | 6.72M | 2.24M | 15.3M | 25.1M | 29.0M |
| Accounts payable | 3.09M | 775.7K | 958.0K | 335.0K | 701.0K | 1.00M | 914.0K | 877.0K | 2.38M | 591.0K |
| Current liabilities | 8.25M | 3.35M | 3.47M | 2.95M | 3.00M | 3.33M | 1.41M | 2.51M | 2.39M | 1.50M |
| Long-term debt | 0 | 1.71M | ||||||||
| Total debt | 3.12M | 93.2K | 44.0K | 85.0K | ||||||
| Total liabilities | 8.28M | 3.41M | 3.47M | 3.00M | 3.00M | 3.33M | 1.41M | 2.51M | 2.39M | 1.50M |
| Shareholders' equity | -4.76M | 6.48M | 9.21M | 5.54M | 14.0M | 3.38M | 830.0K | 12.8M | 22.7M | 27.5M |
| Shares outstanding | 9.00M | 3.71M | 2.72M | 1.45M | 600.6K | 210.7K | 11.6M | 115.6K | 169.4M | 83.5K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -9.98M | -10.6M | -9.28M | -9.61M | -11.3M | -7.32M | -11.8M | -9.82M | -11.6M | -7.91M |
| Capital spending | -48.2K | -37 | -41.0K | -279.0K | -29.0K | -138.0K | -325.0K | -325.0K | -564.0K | -440.0K |
| Free cash flow | -10.0M | -10.6M | -9.32M | -9.89M | -11.3M | -7.46M | -12.1M | -10.1M | -12.1M | -8.35M |
| Cash from investing | -48.2K | -37 | -41.0K | -279.0K | -29.0K | -138.0K | 111.0K | -902.0K | -564.0K | -440.0K |
| Cash from financing | 3.87M | 7.73M | 13.1M | 1.43M | 21.9M | 11.3M | 11.3M | 71.0K | 7.56M | 31.9M |
| Dividends paid | -20.9M | -11.2M | ||||||||
| Share buybacks | -642.0K | -744.0K | 0 | -968.0K | -105.0K | 0 | 71.0K | -511.0K | 35.4M | |
| Change in cash | -6.15M | -2.88M | 3.79M | -9.89M | 10.6M | 3.82M | -11.4M | -10.7M | -4.43M | 23.7M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Change in substantial holding | Nov 19, 2026 | Ownership change notice | ASX |
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 30, 2026 | Quarterly report | ASX |
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 30, 2026 | Quarterly report | ASX |
| Additional $750,000 Loan Facility from Barvest Ventures | Oct 30, 2026 | Financing | ASX |
| Notice of Annual General Meeting/Proxy Form | Oct 28, 2026 | Meeting notice | ASX |
| Partnership with Florida Lung, Asthma & Sleep Specialists | Oct 25, 2026 | Operations update | ASX |
| Appointment of Chief Financial Officer | Oct 11, 2026 | Management or board change | ASX |
| AUD$700,000 Short-Term Loan Facility from Barvest Ventures | Oct 6, 2026 | Other filings | ASX |
| Appendix 4G & Corporate Governance Statement | Sep 30, 2026 | Other filings | ASX |
| Annual Report to shareholders | Sep 30, 2026 | Annual report | ASX |
All 118 filings
Cap table
Built by 6ix from Adherium Ltd.’s releases · as of Feb 18, 2026
- Common shares
- 54,887,674
- Fully diluted
- 54,887,674
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 54,887,674 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 54,887,674 |
| May 20, 2026 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Brad Wilson | Chief Financial Officer · Since at least Oct 11, 2026 |
| Catherine Morgan | Head of Regulatory & Quality · Since at least Nov 4, 2026 |
| Daniel Kaplon | Chief Financial Officer · Since at least Nov 5, 2026 |
| David Haddad | Head of Product · Since at least Nov 4, 2026 |
| Dawn Bitz | CEO · Since at least Sep 16, 2025 |
| George Baran | Non-Executive Chair · Since at least Nov 5, 2026 |
| Hetal Dhruve | Head of Medical & Clinical Affairs · Since at least Nov 4, 2026 |
| James Ward-Lilley | Chairman of the Board · Since at least Nov 5, 2026 |
| Jeremy Curnock Cook | Independent Non-Executive Director · Since at least Nov 5, 2026 |
| John Perry | Interim Chief Executive Officer & Chief Commercial Officer · Since at least Nov 4, 2026 |
All 13 people
| Person | Seat |
|---|---|
| Keven Gessner | Non-Executive Director · Since at least Nov 4, 2026 |
| Lou Panaccio | Independent Non-Executive Director · Since at least Nov 4, 2026 |
| Victoria Durrans | Independent Non-Executive Director · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Adherium Ltd.